Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy

Date

23 Nov 2019

Session

Poster display session

Topics

Immunotherapy

Tumour Site

Presenters

Tsu Yi Chao

Citation

Annals of Oncology (2019) 30 (suppl_9): ix107-ix114. 10.1093/annonc/mdz438

Authors

T.Y. Chao1, C.L. Ho2, W.H. Cheng3, C.L. Chang4, Y.Y. Hsieh1, W. Jiang5, S. Liu5, A. LUK6, S.F. Lin7, T.C. Hsieh7, E. Liu7

Author affiliations

  • 1 Internal Medicine, Division Of Hematology And Oncology, Shuang-Ho hospital, Taipei Medical University, 23561 - New Taipei City/TW
  • 2 Internal Medicine, Division Of Hematology And Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei/TW
  • 3 Internal Medicine, Division Of Hematology And Oncology, School of Medicine, College of Medicine, Taipei Medical University, Taipei/TW
  • 4 Internal Medicine, Division Of Hematology And Oncology, Wan Fang Hospital, Taipei Medical University, Taipei/TW
  • 5 Executive Office, Shanghai Henlius Biotech, Inc., 200233 - Shanghai/CN
  • 6 Global Clinical And Medical Affairs, Shanghai Henlius Biotech, Inc., 200233 - Shanghai/CN
  • 7 Clinical Research And Development, Taiwan Henlix Biotech., Co., LTD., Taipei/TW

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 324P

Background

HLX10, a fully humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor blocking PD-1, increased functional activities of human T-cells and showed in-vitro antitumour activity in xenograft models. The combined inhibition of PD-1 and VEGFR pathways may enhance a sustained suppression of cancer-related angiogenesis and tumour growth. Here, we present the phase 1 study data of HLX10 and the development of HLX10 as targeted combination immunotherapy.

Methods

We conducted an open-label, dose-finding with Bayesian optimal interval adaptive design study to evaluate safety, maximum tolerated dose, PK and clinical activity of HLX10 in patients with advanced or metastatic solid tumours refractory to standard therapy. Patients (pts) received biweekly i.v. infusions of HLX10 at doses of 0.3, 1, 3 and 10 mg/kg until disease progression, intolerable toxicities or withdrawal from the study. The dose-limiting toxicities were observed for 28 days after treatment. Clinical response was evaluated every 8 weeks for the first 24 weeks followed by every 12 weeks. Safety, PK and clinical response evaluations were performed throughout the study.

Results

As of 27-June-2019, 16 pts were dosed with HLX10 at various doses and maintained >90% PD1 receptor occupancy on the peripheral T-cells. Among 13 pts being evaluated for efficacy, 2 pts each at 0.3 and 3 mg/kg cohorts achieved stable disease; 1 pt at 3 mg/kg cohort achieved partial response with the longest follow-up time of 220 days. No infusionrelated reaction or additional safety signal was observed up to 10 mg/kg. The PK profiles demonstrated dose proportional manner as shown in the table.Table:

324P The PK parameters of 0.3 mg/kg and 3 mg/kg cohorts

Dose(mg/kg)Cmax (μg/mL)AUC0-t (h* μg/mL)t1/2 (h)
-C1D1C3D1C1D1C3D1C1D1C3D3
0.35.36.3702.1957.1183.4183.0
374.8117.210823.627750.9259.7489.81

Conclusions

HLX10 is well tolerated, shows promising antitumour activities with durable objective responses in various cancers, and exhibits similar PK results to pembrolizumab and nivolumab. HLX10 is currently being tested in the first China combo-immunotherapy studies with HLX04 (a bevacizumab biosimilar) in advanced solid tumours with the longest follow-up time of > 200 days as of 20-June-2019 and in first-line treatment of metastatic NSCLC.

Clinical trial identification

HLX10-001(Registration Number: NCT0346875) monotherapy in advanced solid tumours; HLX10HLX04-001(Registration Number: NCT03757936) combo-immunotherapy in advanced solid tumours; HLX10-002-NSCLC301(Registration Number: NCT03952403) combo-immunotherapy in NSCLC.

Editorial acknowledgement

Legal entity responsible for the study

Shanghai Henlius Biotech, Inc; Taiwan Henlix Biotech., Co.,LTD.

Funding

Shanghai Henlius Biotech, Inc.

Disclosure

T.Y. Chao: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. C.L. Ho: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. W.H. Cheng: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. C.L. Chang: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. Y.Y. Hsieh: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. W. Jiang: Full / Part-time employment: Shanghai Henlius Biotech, Inc. S. Liu: Full / Part-time employment: Shanghai Henlius Biotech,Inc. A. LUK: Full / Part-time employment: Shanghai Henlius Biotech, Inc. S.F. Lin: Full / Part-time employment: Taiwan Henlix Biotech., Co., LTD. T.C. Hsieh: Full / Part-time employment: Taiwan Henlix Biotech., Co., LTD. E. Liu: Full / Part-time employment: Taiwan Henlix Biotech., Co., LTD.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.